中東およびアフリカの低活動膀胱市場、タイプ別（薬物療法、外科的治療法、尿道補助装置、幹細胞および遺伝子治療）、投与経路別（経口、非経口、その他）、エンドユーザー別（病院、診療所、学術研究機関、その他）、流通チャネル別（病院薬局、小売薬局、その他）業界動向および2029年までの予測
中東およびアフリカの低活動膀胱市場の分析と洞察
中東およびアフリカの低活動膀胱市場は、神経因性膀胱感染症の発生率の上昇、研究資金の増加、低活動膀胱（UAB）の新しい治療法の開発、パイプライン製品による需要の高まり、および市場の成長につながる研究開発への投資の増加などの要因によって推進されています。現在、医療費は先進国と新興国全体で増加しており、メーカーが新しい革新的な製品を開発するための競争上の優位性を生み出すことが期待されています。さらに、医療費の急増と膀胱障害の有病率の増加は、市場にプラスの影響を与えます。
しかし、治療費が高額なため、患者は高品質で効果的な解決策を受け入れることが困難になっています。そのため、治療手順の高額な費用は、全体的な治療費に悪影響を及ぼします。さらに、UAB の治療に現在使用されている薬剤は、有効性と安全性の観点から臨床的に満足できるものではないため、新しい治療薬の開発が必要になります。
中東およびアフリカの活動低下性膀胱市場は、市場プレーヤーの増加と新しいパイプライン薬の存在により、予測期間中に成長すると予想されています。これに伴い、メーカーは市場に新しい製品を投入するための研究開発活動に取り組んでいます。
しかし、研究や調査に関連するコストが高いため、市場の成長が抑制され、市場での新製品の発売にさらに影響を与える可能性があります。
革新的で効果的な治療法の新たな開発を促進するための研究開発プログラムの増加と官民パートナーシップの増加が、市場にさらなる影響を与えています。
中東およびアフリカの活動不全膀胱市場レポートは、市場シェア、新開発、製品パイプライン分析、国内および現地の市場プレーヤーの影響の詳細を提供し、新たな収益源、市場規制の変更、製品承認、戦略的決定、製品発売、地理的拡大、市場における技術革新の観点から機会を分析します。分析と市場シナリオを理解するには、アナリスト概要についてお問い合わせください。当社のチームが、収益に影響を与えるソリューションを作成し、目的の目標を達成するお手伝いをします。さまざまな地域の発展途上国における小売ユニットの拡張性と事業拡大、および機械および医薬品製品の安全な流通のためのサプライヤーとのパートナーシップは、予測期間における市場の需要を推進した主な原動力です。
中東およびアフリカの活動低下膀胱市場は支援的であり、病気の進行を抑えることを目指しています。データブリッジマーケットリサーチは、中東およびアフリカの活動低下膀胱市場は2022年から2029年の予測期間中に3.5%のCAGRで成長すると分析しています。
|
レポートメトリック |
詳細 |
|
予測期間 |
2022年から2029年 |
|
基準年 |
2021 |
|
歴史的な年 |
2020 |
|
定量単位 |
売上高は百万米ドル、価格は米ドル |
|
対象セグメント |
タイプ別（薬物療法、外科的治療、尿道補助装置、幹細胞および遺伝子治療）、投与経路別（経口、非経口、その他）、エンドユーザー別（病院、診療所、学術研究機関、その他）、流通チャネル別（病院薬局、小売薬局、その他） |
|
対象国 |
サウジアラビア、南アフリカ、UAE、イスラエル、クウェート、エジプト、その他の中東およびアフリカ諸国 |
|
対象となる市場プレーヤー |
アステラス製薬株式会社、オーロビンドファーマ、ベーリンガーインゲルハイムインターナショナルGmbH、マクロードファーマシューティカルズリミテッド、オリオンコーポレーション、ノバルティスAG、ファイザー株式会社、シプラ株式会社、テバファーマシューティカルインダストリーズリミテッド、サンファーマシューティカルインダストリーズリミテッド、アルミラルSA、アルケムラボラトリーズなど |
市場の定義
低活動膀胱（ＵＡＢ）は、排尿時に膀胱の排尿筋（デトルサーマッスル）の収縮力が低下することにより排尿障害を呈する病態であり、すぐに尿意を感じるのが特徴であり、過活動膀胱とは異なる。本発明は、尿流量改善効果、膀胱の過膨張改善効果（膀胱容量減少効果）を有し、ＵＡＢの予防または治療に有用な、ＵＡＢの予防または治療に有用な医薬組成物を提供する。
また、近年注目されている尿意切迫感を特徴とする過活動膀胱とは異なる病態です。過活動膀胱の原因としては、糖尿病やアルコール依存症などの自律神経障害、広汎子宮全摘出術や直腸がんなどの骨盤内手術、二分脊椎などの脊髄疾患、椎間板ヘルニアなどが知られています。重症および軽症の膀胱障害に伴う問題を抱える患者は、薬物療法が必要となり、複数の治療法を繰り返すことが多く、十分な効果が得られないまま治療を継続するなど、医療費にも影響を与えています。
中東およびアフリカの低活動膀胱市場の動向
このセクションでは、市場の推進要因、機会、制約、課題について理解します。これらはすべて、以下で詳しく説明します。
ドライバー
- 神経疾患の罹患率の増加
UAB は、神経と筋肉がうまく連携できず、排尿時間が長くなり、膀胱が空っぽにならない感覚がある場合とない場合がある一般的な神経疾患です。この疾患では、排尿筋の収縮活動が不十分になり、尿の流れが遅くなり、排尿が遅くなり、排尿に力を入れるのが困難になります。膀胱が空っぽにならない感覚がある場合とない場合があり、貯留症状が現れることもあります。そのため、膀胱筋が尿を適切に排出できないため、膀胱は空にならないか、部分的にしか空になりません。
そのため、UABの患者はさまざまな排尿症状を呈し、多量の残尿を伴うことがあります。重症化による尿閉や慢性残尿による尿路感染症（UTI）などの合併症が多く見られ、問題となっています。また、近年注目されている尿意切迫感を特徴とするOABとは異なる病態です。そのため、神経因性膀胱障害の有病率増加が市場の成長を牽引すると予想されます。これにより、患者も検出できる治療の需要が高まり、市場の大幅な成長が期待されます。
- 医療費の増大
研究者に危害が及んだ場合の器具、人材、医療管理、保険、輸送、倫理委員会の費用、データ処理、その他の消耗品は、市場参加者にとって大きなコスト負担となります。医療費は、すべての医療サービス、検査機器、家族計画活動、および健康を目的とした緊急援助で構成されます。国民健康勘定は、国際的に認められた枠組み内で収集された支出に基づく多くの指標を提供します。どの国の医療費も決定する要因は、所得（一人当たりのGDP）、医療行為における技術進歩と変化、および医療システムの特徴です。
医療費の増加は、同時に、医療機関や政府機関が更年期障害治療薬の研究活動、今後の臨床試験、研究開発活動を増やすのに役立ちます。また、新製品の生産と製造にかかるコストを考えると、市場プレーヤーは十分な資金とリソースを割り当てる必要があるため、政府はこのシナリオで援助の役割を果たします。医療費の増加は、医療部門のさらなる経済発展と成長にも有益です。さらに、人口の可処分所得の増加は好ましい要因です。したがって、医療費の増加は、将来的に市場の成長を促進すると予想されます。
機会
- 糖尿病の泌尿器合併症の増加
UAB の既知の原因の 1 つに、糖尿病などの自律神経障害があります。さらに、糖尿病は泌尿器疾患の早期発症と重症度の増加に関連し、高額で衰弱させる泌尿器合併症を引き起こします。膀胱機能障害や尿路感染症などのこれらの泌尿器合併症は、糖尿病の男性と女性の両方のクオリティ オブ ライフに深刻な影響を及ぼします。糖尿病と泌尿器疾患は非常に一般的な健康問題であり、加齢とともに有病率と発症率が著しく増加します。糖尿病の泌尿器合併症は即時の影響です。糖尿病は最も顕著な疾患であり、世界中で高い有病率を誇っています。
糖尿病関連の膀胱合併症は、排尿筋平滑筋の変化、神経機能障害、尿路上皮機能障害が原因である可能性があります。関与する神経に応じて、糖尿病性神経障害の影響は、脚の不快感やしびれから、消化器系、尿路、血管、体幹の合併症まで多岐にわたります。糖尿病に関するデータの増加により、世界中で糖尿病の泌尿器合併症のリスクが大幅に増加します。したがって、糖尿病の泌尿器合併症の適切な治療のための研究と臨床ケアの将来の方向性を推奨する必要があります。無視されている合併症に取り組むために、開発途上地域に到達するには、他の組織からの支援も必要になります。したがって、これは糖尿病の泌尿器合併症の増加が市場成長の機会として機能すると予想されることを意味します。
抑制/挑戦
- 研究開発（R&D）コストが高い
R&D is a prerequisite in modifying the procedure intended to treat different kinds of patients. The higher cost of R&D for new products demands deep research and clinical studies. The various clinical phases in R&D require huge investments which can affect market growth. The research cost involved in planning and execution of the studies, and research requires adequate allocation of funds and resources, which can affect new developments in the market. The cost of the product plays a major factor in the market. Many diagnostic options are available in the market, but due to their high cost, most people tend to avoid going for a diagnosis. Diagnostic approaches have come with greater sensitivity and specificity cost of the test also increased.
The high cost of the procedure is due to various checkpoints of treatments along with the use of high-tech modalities to perform such procedures. As cost of R&D for treatments is too high, it restricts accommodating high-quality and effective solutions. Henceforth, the high cost negatively impacts the cost of overall treatment. Consequently, it will constrict the future demand for treatment in low and middle-income countries. This suggests that the high cost associated with the research and studies is expected to restrain market growth which can further impact the launch of new products in the market.
Post COVID-19 Impact on Middle East and Africa Underactive Bladder Market
COVID-19 has positively affected in the growth of the market as there is rise in the demand for products widely in the region. People have become more health conscious as there is rising prevalence of various bladder diseases in the region. Complications of urinary retention due to aggravation and UTIs due to chronic residual urine are often seen and have become a problem. Hence, COVID-19 has impacted positively on this market.
Recent Developments
- In June 2020, Vesiflo, Inc. announced the medicare coverage of inFlow urinary prosthesis, a magnetically coupled FDA-approved intraurethral valve-pump device which can be used for 29 days by adult women as an alternative to intermittent catheterization. This results in a contribution to the expansion of product business quickly with commercialization in the market.
- In April 2020, Astellas Pharma Europe Ltd. completed a clinical trial that was conducted on subjects for the treatment of underactive bladder. Currently, ASP8302 is under phase-2 clinical trial to investigate the safety and tolerability of the drug in patients with underactive bladder.
Middle East and Africa Underactive Bladder Market Scope
Middle East and Africa underactive bladder market is categorized into four notable segments based on type, route of administration, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Type
- Pharmacotherapy
- Surgical Methods
- Urethral Assist Device
- Stem Cell and Gene Therapies
Based on type, the market is segmented into pharmacotherapy, surgical methods, urethral assist device, and stem cell and gene therapies.
Route of Administration
- Oral
- Parenteral
- Others
Based on route of administration, the market is segmented into oral, parenteral, and others.
End User
- Hospitals
- Clinics
- Academic and Research Institutes
- Others
Based on end user, the market is segmented into hospitals, clinics, academic and research institutes, and others.
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Others
Based on distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and others.
Middle East and Africa Underactive Bladder Market Regional Analysis/Insights
Middle East and Africa underactive bladder market is analyzed and market size insights and trends are provided by type, route of administration, end user, and distribution channel as referenced above.
The countries covered in the Middle East and Africa underactive bladder market report are Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, and rest of Middle East and Africa.
In 2022, Middle East and Africa underactive bladder market is expected to grow due to the increasing prevalence of bladder disorders and growing geriatric population. The technological advances for the treatment of bladder disorders and the rise in product approvals are also boosting market growth.
South Africa is expected to dominate due to the presence of big market players and an established healthcare system to treat bladder disorders.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Middle East and Africa Underactive Bladder Market Share Analysis
Middle East and Africa underactive bladder market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Middle East and Africa presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on the Middle East and Africa underactive bladder market.
Some players in the market are
- Astellas Pharma Inc.
- Aurobindo Pharma.
- ベーリンガーインゲルハイムインターナショナルGmbH
- マクロード製薬株式会社
- オリオン株式会社
- ノバルティスAG
- ファイザー株式会社
- シプラ株式会社
- テバ製薬株式会社
- サンファーマシューティカルインダストリーズ株式会社
- アルミラル、SA
- アルケムラボ。
研究方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。市場データは、市場統計モデルとコヒーレント モデルを使用して分析および推定されます。さらに、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数の市場への影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。これとは別に、データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、企業市場シェア分析、測定基準、中東とアフリカ対国、ベンダー シェア分析が含まれます。さらに問い合わせる場合は、アナリストへの電話をリクエストしてください。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT SEGMENT LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
4.3 EPIDEMIOLOGY
4.4 THE IMPORTANCE OF UNDERSTANDING PATENTS-
4.4.1 DOXAZOSIN
4.4.2 BETHANECHOL CHLORIDE
4.4.3 TAMSULOSIN HYDROCHLORIDE
4.5 CLINICAL TRIALS FOR UNDERACTIVE BLADDER
4.5.1 EU CLINICAL TRIALS REGISTER-
4.6 MERGER & ACQUISITION IN HEALTHCARE INDUSTRY
4.7 M&A DEALS IN 2021 BY TARGET COMPANY TERRITORY:
4.8 CROSS-BORDER DEALS:
4.9 OUTLOOK FOR 2022:
4.1 PATIENT ENROLMENT STRATEGIES
4.11 FACTORS AFFECTING PATIENT RECRUITMENT:
4.12 CHALLENGES:
4.13 PATIENT FUNNEL ANALYSIS:
4.14 RECOMMENDATIONS
4.14.1 USE OF TECHNOLOGY:
4.14.2 PARTICIPANT CHARACTERISTICS:
4.14.3 RECRUITER CHARACTERISTICS:
4.14.4 SYSTEMS & PROCEDURES:
4.14.5 LOCATION:
4.14.6 NATURE OF RESEARCH:
4.15 CONCLUSION:
4.16 UNDERACTIVE BLADDER PATIENT FLOW DIAGRAM
4.17 WHAT CAUSES UNDERACTIVE BLADDER?
4.17.1 CAUSES OF UNDERACTIVE BLADDER INCLUDE
4.17.2 TESTS TO EVALUATE UNDERACTIVE BLADDER
4.18 UNDERACTIVE BLADDER INVESTIGATIONAL PRODUCTS-
5 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: REGULATIONS
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING PREVALENCE OF NEUROGENIC DISORDER
6.1.2 INCREASE IN RESEARCH AND DEVELOPMENT OF UNDERACTIVE BLADDER TREATMENT
6.1.3 FAVOURABLE REIMBURSEMENT SCENARIO
6.1.4 RISING HEALTHCARE EXPENDITURE
6.2 RESTRAINTS
6.2.1 HIGH COST OF RESEARCH AND DEVELOPMENT
6.2.2 STRINGENT GOVERNMENT REGULATIONS ON NEW PRODUCTS APPROVAL
6.3 OPPORTUNITIES
6.3.1 RISING UROLOGIC COMPLICATIONS OF DIABETES
6.3.2 PRESENCE OF NOVEL PIPELINE DRUGS
6.3.3 IMPROVING A BETTER HEALTHCARE SYSTEM
6.4 CHALLENGES
6.4.1 LACK OF PROPER TREATMENT
6.4.2 RISK INVOLVED DURING TREATMENT OF UNDERACTIVE BLADDER
7 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET, BY TYPE
7.1 OVERVIEW
7.2 PHARMACOTHERAPY
7.2.1 ALPHA-BLOCKERS
7.2.2 MUSCARINIC AGONISTS
7.2.3 CHOLINESTERASE INHIBITOR
7.2.3.1 BY DRUGS
7.2.3.1.1 TAMSULOSIN
7.2.3.1.2 DOXAZOSIN
7.2.3.1.3 DISTIGMINE
7.2.3.1.4 BETHANECHOL
7.2.3.1.5 OTHERS
7.2.4 BY PRODUCT TYPES
7.2.4.1 GENERICS
7.2.4.2 BRANDED
7.2.4.2.1 FLOMAX
7.2.4.2.2 ALFADIL
7.2.4.2.3 GRAVITOR
7.2.4.2.4 URIVOID
7.2.4.2.5 OTHERS
7.3 SURGICAL METHODS
7.3.1 SURGICAL NERVE STIMULATION
7.3.2 REDUCTION CYSTOPLASTY
7.3.3 SURGERIES FOR BLADDER OBSTRUCTION
7.3.4 INJECTION INTO EXTERNAL SPHINCTER
7.3.5 OTHERS
7.4 URETHRAL ASSIS DEVICE
7.4.1 INFLOW INTRAURETHRAL VALVE PUMP
7.5 STEM CELL AND GENE THERAPIES
7.5.1 NERVE GROWTH FACTOR
7.5.2 GLIAL-CELL DERIVE NEUTOPHIC FACTORGLIAL
7.5.3 NEUTOPHIN-3 DERIVES FROM GLIALL CELLS
8 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET,BY ROUTE OF ADMINISTRATION
8.1 OVERVIEW
8.2 PARENTERAL
8.3 ORAL
8.4 OTHERS
9 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET , BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 CLINICS
9.4 ACADEMIC AND RESEARCH
9.5 OTHERS
10 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET , BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 HOSPITAL PHARMACY
10.3 RETAIL PHARMACY
10.4 OTHERS
11 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET, BY REGION
11.1 MIDDLE EAST AND AFRICA
11.1.1 SOUTH AFRICA
11.1.2 SAUDI ARABIA
11.1.3 U.A.E
11.1.4 ISRAEL
11.1.5 EGYPT
11.1.6 KUWAIT
11.1.7 REST OF MIDDLE EAST AND AFRICA
12 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
13 SWOT ANALYSIS
14 COMPANY PROFILES
14.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
14.1.1 COMPANY SNAPSHOT
14.1.2 COMPANY SHARE ANALYSIS
14.1.3 PRODUCT PORTFOLIO
14.1.4 RECENT DEVELOPMENT
14.2 PFIZER INC.
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENT
14.3 SUN PHARMACEUTICAL INDUSTRIES LTD.
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENT
14.4 TEVA PHARMACEUTICAL INDUSTRIES LTD
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENT
14.5 NOVARTIS AG
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENT
14.6 DR. REDDY’S LABORATORIES LTD.
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENT
14.7 ASTELLAS PHARMA INC.
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT
14.8 ORION CORPORATION.
14.8.1 COMPANY SNAPSHOT
14.8.2 REVENUE ANALYSIS
14.8.3 PRODUCT PORTFOLIO
14.8.4 RECENT DEVELOPMENT
14.9 ALKEM LABS.
14.9.1 COMPANY SNAPSHOT
14.9.2 REVENUE ANALYSIS
14.9.3 PRODUCT PORTFOLIO
14.9.4 RECENT DEVELOPMENT
14.1 ALMIRALL, S.A
14.10.1 COMPANY SNAPSHOT
14.10.2 REVENUE ANALYSIS
14.10.3 PRODUCT PORTFOLIO
14.10.4 RECENT DEVELOPMENT
14.11 AUROBINDO PHARMA.
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENT
14.12 CIPLA INC.
14.12.1 COMPANY SNAPSHOT
14.12.2 REVENUE ANALYSIS
14.12.3 PRODUCT PORTFOLIO
14.12.4 RECENT DEVELOPMENT
14.13 GLENWOOD
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENT
14.14 MACLEODS PHARMACEUTICALS LTD.
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENT
14.15 ONO PHARMACEUTICAL CO., LTD.
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENT
14.16 VESIFLO, INC.
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
表のリスト
TABLE 1 TOTAL 40 DOXAZOSIN DRUGS WERE DISCONTINUED FROM THE MARKET
TABLE 2 TOTAL 38 DOXAZOSIN DRUGS ARE STILL IN THE MARKET
TABLE 3 TOTAL PRESCRIPTION AND DISCONTINUED DRUGS (DOXAZOSIN) BY COMPANY
TABLE 4 TOTAL 58 DRUGS DISCONTINUED
TABLE 5 TOTAL PRESCRIPTION AND DISCONTINUED DRUGS (BETHANECHOL CHLORIDE) BY COMPANY
TABLE 6 OUT OF 3,128 STUDIES ON BLADDER DISORDER, ONLY 22 STUDIES ARE ONGOING FOR THE UAB-
TABLE 7 THESE CLINICAL TRIALS ARE MOSTLY RECRUITING/ONGOING IN DIFFERENT REGIONS OF THE WORLD-
TABLE 8 TOP ACQUISITIONS OF 2021 RANKED BY TOTAL DEAL VALUE:
TABLE 9 FDA REQUIRES THE FOLLOWING SCENARIO BEFORE A DRUG IS APPROVED
TABLE 10 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET, TYPE, 2020-2029 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA BY PRODUCT TYPE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA BRANDED IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA STEM CELL AND GENE THERAPIES IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET , BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA PARENTERAL IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA ORAL IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA OTHERS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET , BY END USER, 2020-2029 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA HOSPITALS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA CLINICS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA ACADEMIC AND RESEARCH IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA OTHERS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET , BY DISTRIBUTION CHANNEL , 2020-2029 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA HOSPITAL PHARMACY IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA RETAIL PHARMACY IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA OTHERS IN UNDERACTIVE BLADDER MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 42 MIDDLE EAST AND AFRICA BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 43 MIDDLE EAST AND AFRICA BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 46 MIDDLE EAST AND AFRICA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 47 MIDDLE EAST AND AFRICA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 51 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 52 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 53 SOUTH AFRICA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 SOUTH AFRICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 55 SOUTH AFRICA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 56 SOUTH AFRICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 57 SOUTH AFRICA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 58 SOUTH AFRICA BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 59 SOUTH AFRICA BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 60 SOUTH AFRICA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 61 SOUTH AFRICA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 62 SOUTH AFRICA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 63 SOUTH AFRICA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 64 SOUTH AFRICA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 65 SOUTH AFRICA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 66 SOUTH AFRICA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 67 SOUTH AFRICA UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 68 SOUTH AFRICA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 69 SAUDI ARABIA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 70 SAUDI ARABIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 71 SAUDI ARABIA PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 72 SAUDI ARABIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 73 SAUDI ARABIA BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 74 SAUDI ARABIA BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 75 SAUDI ARABIA BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 76 SAUDI ARABIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 77 SAUDI ARABIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 78 SAUDI ARABIA BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 79 SAUDI ARABIA SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 80 SAUDI ARABIA URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 81 SAUDI ARABIA STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 82 SAUDI ARABIA UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 83 SAUDI ARABIA UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 84 SAUDI ARABIA UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 85 U.A.E UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 86 U.A.E PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 87 U.A.E PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 88 U.A.E BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 89 U.A.E BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 90 U.A.E BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 91 U.A.E BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 92 U.A.E BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 93 U.A.E BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 94 U.A.E BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 95 U.A.E SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 96 U.A.E URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 97 U.A.E STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 98 U.A.E UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 99 U.A.E UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 100 U.A.E UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 101 ISRAEL UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 102 ISRAEL PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 103 ISRAEL PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 104 ISRAEL BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 105 ISRAEL BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 106 ISRAEL BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 107 ISRAEL BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 108 ISRAEL BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 109 ISRAEL BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 110 ISRAEL BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 111 ISRAEL SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 112 ISRAEL URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 113 ISRAEL STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 114 ISRAEL UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 115 ISRAEL UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 116 ISRAEL UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 117 EGYPT UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 118 EGYPT PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 119 EGYPT PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 120 EGYPT BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 121 EGYPT BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 122 EGYPT BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 123 EGYPT BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 124 EGYPT BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 125 EGYPT BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 126 EGYPT BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 127 EGYPT SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 128 EGYPT URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 129 EGYPT STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 130 EGYPT UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 131 EGYPT UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 132 EGYPT UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 133 KUWAIT UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 134 KUWAIT PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 135 KUWAIT PHARMACOTHERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 136 KUWAIT BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 137 KUWAIT BY DRUGS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 138 KUWAIT BY DRUGS UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 139 KUWAIT BY PRODUCT TYPE UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 140 KUWAIT BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 141 KUWAIT BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 142 KUWAIT BRANDED UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 143 KUWAIT SURGICAL METHODS IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 144 KUWAIT URETHRAL ASSIS DEVICE IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 145 KUWAIT STEM CELL AND GENE THERAPY IN UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 146 KUWAIT UNDERACTIVE BLADDER MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 147 KUWAIT UNDERACTIVE BLADDER MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 148 KUWAIT UNDERACTIVE BLADDER MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 149 REST OF MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET, BY TYPE, 2020-2029 (USD MILLION)
図表一覧
FIGURE 1 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: SEGMENTATION
FIGURE 11 INCREASING PREVALENCE OF NEUROGENIC BLADDER INFECTIONS IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET IN THE FORECAST PERIOD
FIGURE 12 TREATMENT SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET
FIGURE 14 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : TYPE, 2021
FIGURE 15 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : TYPE, 2022-2029 (USD MILLION)
FIGURE 16 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : TYPE, CAGR (2022-2029)
FIGURE 17 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : TYPE, LIFELINE CURVE
FIGURE 18 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, 2021
FIGURE 19 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)
FIGURE 20 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 21 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 22 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY END USER, 2021
FIGURE 23 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY END USER, 2022-2029 (USD MILLION)
FIGURE 24 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY END USER, CAGR (2022-2029)
FIGURE 25 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY END USER, LIFELINE CURVE
FIGURE 26 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, 2021
FIGURE 27 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 28 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 29 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 30 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET: SNAPSHOT (2021)
FIGURE 31 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET: BY COUNTRY (2021)
FIGURE 32 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET: BY COUNTRY (2022 & 2029)
FIGURE 33 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET: BY COUNTRY (2021 & 2029)
FIGURE 34 MIDDLE EAST AND AFRICA UNDERACTIVE BLADDER MARKET: BY TYPE (2022-2029)
FIGURE 35 MIDDLE EAST & AFRICA UNDERACTIVE BLADDER MARKET: COMPANY SHARE 2021 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
